Prominent pharmaceutical industry figures like Jan van de Winkel and Deborah Dunsire from Genmab and Lundbeck, respectively, are joining top executives at Novo Nordisk and Novozymes in a small but exclusive club of C25 companies which integrate ESG indicators into their management incentive schemes.
In this vein, C25's pharmaceutical companies are aligning themselves with a globally growing trend involving the establishment of financial management incentives which work towards attaining sustainability goals, which Danish financial media Økonomisk Ugebrev Samfundsansvar writes after going over executive incentive plans at C25 companies.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.